Main Article Content


The 3-(benzylideneamino)-2-(2,4-dichlorophenyl)-quinazoline-4(3H)-ones (BDCQ) are compounds developed as anticancer drugs and quinazolines. The activity and bioavailability of BDCQ derivatives as anticancer compounds that inhibit COX-2 can be predicted by computer programs and online servers. Substituents are added at positions 2 and 3 to the quinazoline-4(3H)-on ring, such as -H, -NO2, -OCH3, -N(CH3)2, -SO2NH2, -OH, and –OCH3. QSAR as COX-2 inhibitor analysis was performed by SPSS Ver. 21 software. Lipinski’s rule of five for determining bioavailability is performed by an online server at The best QSAR equation used to predict the COX-2 inhibitors from these compounds is RS-pred = 0.372 Log P + 0.014 MR + 0.979 Etot – 4.859, with n= 12, R = 0.998; SE = 0.356, F = 805.252 and sig = 0.001. Six compounds were predicted to have good oral bioavailability, such as 3-(benzylideneamino)-2-(2,4-dichlorophenyl)quinazoline-4(3H)-one, 2-(2,4-dichlorophenyl)-3-((2-nitrobenzylidene)amino)quinazoline-4(3H)-one, 2-(2,4-dichlorophenyl)-3-((3-nitrobenzylidene)amino)quinazoline-4(3H)-one,  2-(2,4-dichlorophenyl)-3-((2-methoxybenzilidene)amino)quinazoline-4(3H)-one, 2-(2,4-dichlorophenyl)-3-((3-methoxybenzylidene)amino)quinazolin-4(3H)-one,  and 2-(((2-(2,4-dichlorophenyl)-4-oxoquinazolin-3(4H)-yl)imino)methyl)- benzenesulfonamide. This research can be used as an in vitro and in vivo study for BDCQ derivatives as anticancer drugs.



COX-2 inhibitor Lipinski’s rule of five QSAR Quinazolin-4(3H)-one

Article Details


  1. Allaj, V., Guo, C., & Nie, D. (2013). Non-steroid anti-inflammatory drugs, prostaglandins, and cancer. Cell & bioscience, 3(1), 1-13.
  2. Blundell, T. L., Sibanda, B. L., Montalvão, R. W., Brewerton, S., Chelliah, V., Worth, C. L., Harmer, N. J., Davies, O., & Burke, D. (2006). Structural biology and bioinformatics in drug design: Opportunities and challenges for target identification and lead discovery. Philosophical Transactions of the Royal Society B: Biological Sciences, 361(1467), 413–423.
  3. Bott, R. (2014). Data dan Informasi Kesehatan Situasi Penyakit Kanker. Igarss 2014, 1, 1–5.
  4. Chauhan, J. S., Dhanda, S. K., Singla, D., Agarwal, S. M., & Raghava, G. P. S. (2014). QSAR-based models for designing quinazoline/imidazothiazoles/ pyrazolopyrimidines based inhibitors against wild and mutant EGFR. PLoS ONE, 9(7).
  5. Cnr, Q. C. N. R., & Date, R. (2014). Quinazolines Synthesis. June, 1–6.
  6. De Oliveira, C. S., Lira, B. F., Falcao-Silva, V. D. S., Siqueira-Junior, J. P., Barbosa-Filho, J. M., & De Athayde-Filho, P.
  7. F. (2012). Synthesis, molecular properties prediction, and anti-staphylococcal activity of N-acylhydrazones and new 1,3,4-oxadiazole derivatives. Molecules, 17(5), 5095–5107.
  8. Dong, J., Wang, N. N., Yao, Z. J., Zhang, L., Cheng, Y., Ouyang, D., Lu, A. P., & Cao, D. S. (2018). Admetlab: A platform for systematic ADMET evaluation based on a comprehensively collected ADMET database. Journal of Cheminformatics, 10(1), 1–11.
  9. El-Azab, A. S., Al-Omar, M. A., Abdel-Aziz, A. A. M., Abdel-Aziz, N. I., El-Sayed, M. A. A., Aleisa, A. M., Sayed-Ahmed, M. M., & Abdel-Hamide, S. G. (2010). Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: Molecular docking study. European Journal of Medicinal Chemistry, 45(9), 4188–4198.
  10. Ibrahim, M. T., Uzairu, A., Uba, S., & Shallangwa, G. A. (2020). Computational modeling of novel quinazoline derivatives as potent epidermal growth factor receptor inhibitors. Heliyon, 6(2), e03289.
  11. Jiang, D., Lei, T., Wang, Z., Shen, C., Cao, D., & Hou, T. (2020). ADMET evaluation in drug discovery. 20. Prediction of breast cancer resistance protein inhibition through machine learning. Journal of Cheminformatics, 12(1), 1–26.
  12. N. Noolvi, M., M. Patel, H., & Bhardwaj, V. (2011). A Comparative QSAR Analysis of Quinazoline Analogues as Tyrosine Kinase (erbB-2) Inhibitors. Medicinal Chemistry, 7(3), 200–212.
  13. Noolvi, M. N., & Patel, H. M. (2013). A comparative QSAR analysis and molecular docking studies of quinazoline derivatives as tyrosine kinase (EGFR) inhibitors: A rational approach to anticancer drug design. Journal of Saudi Chemical Society, 17(4), 361–379.
  14. Siswandono & Soekardjo B. (2000). Kimia Medisinal 1. Airlangga University Press.
  15. Sobolewski, C., Cerella, C., Dicato, M., Ghibelli, L., & Diederich, M. (2010). The Role of Cyclooxygenase-2 in Cell Proliferation and Cell Death in Human Malignancies. International Journal of Cell Biology, 2010, 1–21.
  16. Widiyana, A.P., Putra, G.S., Muchlashi, & L. (2016). Design and Molecular Docking Studies of Quinazoline Derivatives as Antiproliferation. Jurnal Farmasi dan Ilmu Kefarmasian Indonesia Vol. 3 No. 1 Juli 2016 32. 3(1), 32–38.
  17. Zayed, M. F., Ahmed, H. E. A., Ihmaid, S., Omar, A. S. M., & Abdelrahim, A. S. (2015). Synthesis and screening of some new fluorinated quinazolinone-sulphonamide hybrids as anticancer agents. Journal of Taibah University Medical Sciences, 10(3), 333–339.